Trials / Unknown
UnknownNCT01002703
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma After Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- University of Leipzig · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Define maximum tolerable dose of the combination lenalidomide, bendamustine, prednisone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide, Bendamustine, Prednisone | During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2012-10-01
- Completion
- 2014-10-01
- First posted
- 2009-10-27
- Last updated
- 2011-08-12
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01002703. Inclusion in this directory is not an endorsement.